Author:
Kong Lingti,Rong Li,Xie Mengyuan,Wang Muhua
Subject
Pharmaceutical Science,Pharmacology
Reference15 articles.
1. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology;Ajani;J. Nat. Compreh. Cancer Network : JNCCN,2022
2. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan;Ando;Ann. Oncol.,1998
3. Dosage adjustment of irinotecan in patients with UGT1A1 polymorphisms: a review of current literature;Argevani;Innov. Pharm.,2020
4. A computational approach to predict multi-pathway drug-drug interactions: a case study of irinotecan, a colon cancer medication;Assiri;Saudi Pharm. J.,2020
5. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology;Benson;J. Nat. Compreh. Cancer Network : JNCCN,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献